MX2023008701A - Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38). - Google Patents

Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38).

Info

Publication number
MX2023008701A
MX2023008701A MX2023008701A MX2023008701A MX2023008701A MX 2023008701 A MX2023008701 A MX 2023008701A MX 2023008701 A MX2023008701 A MX 2023008701A MX 2023008701 A MX2023008701 A MX 2023008701A MX 2023008701 A MX2023008701 A MX 2023008701A
Authority
MX
Mexico
Prior art keywords
inhibitors
azaquinolines
quinolines
cancer
compounds
Prior art date
Application number
MX2023008701A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Wayne Kuntz
Melissa Marie Vasbinder
Laurie B Schenkel
Jennifer Downing
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2023008701A publication Critical patent/MX2023008701A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023008701A 2021-01-29 2022-01-28 Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38). MX2023008701A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143245P 2021-01-29 2021-01-29
PCT/US2022/014221 WO2022165114A1 (en) 2021-01-29 2022-01-28 Quinolines and azaquinolines as inhibitors of cd38

Publications (1)

Publication Number Publication Date
MX2023008701A true MX2023008701A (es) 2023-11-29

Family

ID=80446310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008701A MX2023008701A (es) 2021-01-29 2022-01-28 Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38).

Country Status (25)

Country Link
US (2) US11952377B2 (cg-RX-API-DMAC7.html)
EP (2) EP4674415A3 (cg-RX-API-DMAC7.html)
JP (2) JP7777596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230141799A (cg-RX-API-DMAC7.html)
CN (1) CN117580829A (cg-RX-API-DMAC7.html)
AR (1) AR124718A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022212035A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023014898A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208851A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023002163A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023009803A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230323A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000142A (cg-RX-API-DMAC7.html)
EC (1) ECSP23056223A (cg-RX-API-DMAC7.html)
ES (1) ES3042412T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251111T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072981T2 (cg-RX-API-DMAC7.html)
IL (1) IL304466A (cg-RX-API-DMAC7.html)
JO (1) JOP20230160A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023008701A (cg-RX-API-DMAC7.html)
PE (1) PE20232047A1 (cg-RX-API-DMAC7.html)
PL (1) PL4284511T3 (cg-RX-API-DMAC7.html)
RS (1) RS67253B1 (cg-RX-API-DMAC7.html)
TW (1) TW202241418A (cg-RX-API-DMAC7.html)
WO (1) WO2022165114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
CN117715897A (zh) 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途
WO2024217995A1 (en) 2023-04-20 2024-10-24 Syngenta Crop Protection Ag Pesticidally active dihydropyridinone derivatives
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026143058A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Pyridopyrimidine compounds useful as cd38 inhibitors
WO2026143049A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Aminoquinolinones useful as cd38 inhibitors
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
AU2012332297B2 (en) 2011-11-04 2016-01-07 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
CN107428733A (zh) 2014-12-03 2017-12-01 葛兰素史克知识产权第二有限公司 Cd38抑制剂和治疗方法
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
US20230025807A1 (en) 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
KR20230051425A (ko) 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제

Also Published As

Publication number Publication date
JP2025160175A (ja) 2025-10-22
TW202241418A (zh) 2022-11-01
ECSP23056223A (es) 2023-11-30
EP4674415A3 (en) 2026-03-04
CL2023002163A1 (es) 2024-01-05
PE20232047A1 (es) 2023-12-27
CA3208851A1 (en) 2022-08-04
JP2024506814A (ja) 2024-02-15
JOP20230160A1 (ar) 2023-07-20
US11952377B2 (en) 2024-04-09
EP4284511A1 (en) 2023-12-06
IL304466A (en) 2023-09-01
HUE072981T2 (hu) 2025-12-28
EP4674415A2 (en) 2026-01-07
US20240279224A1 (en) 2024-08-22
PL4284511T3 (pl) 2025-12-22
JP7777596B2 (ja) 2025-11-28
AU2022212035A1 (en) 2023-08-03
ES3042412T3 (en) 2025-11-20
RS67253B1 (sr) 2025-10-31
WO2022165114A1 (en) 2022-08-04
AU2022212035A9 (en) 2025-03-06
BR112023014898A2 (pt) 2023-10-31
KR20230141799A (ko) 2023-10-10
EP4284511B1 (en) 2025-07-16
HRP20251111T1 (hr) 2025-11-21
CN117580829A (zh) 2024-02-20
DOP2023000142A (es) 2023-08-31
AR124718A1 (es) 2023-04-26
CO2023009803A2 (es) 2023-10-09
CL2024001535A1 (es) 2024-11-04
US20220242862A1 (en) 2022-08-04
EP4284511C0 (en) 2025-07-16
CR20230323A (es) 2023-10-02

Similar Documents

Publication Publication Date Title
MX2025003444A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
JOP20230160A1 (ar) مركبات كينولين ومركبات آزا كينولين كمثبطات لـ cd38
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
MX2024005228A (es) Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MY191796A (en) Heterocyclic compounds as lsd1 inhibitors
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
PH12021552588A1 (en) Cd73 inhibitors
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
WO2019023315A3 (en) Rac inhibitors
WO2024006292A3 (en) Methods of treating cancer
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2024004874A (es) Compuestos heterociclicos para uso en el tratamiento de cancer.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
MX2023005501A (es) Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.
JOP20240130A1 (ar) مثبطات تفاعل منين-mll